Shots:
- Philogen collaborates with J&J to discover & develop therapies utilizing Philochem’s technology (a Swizz subsidiary of Philogen) for serious conditions
- Philogen signs a development and commercialization agreement with Celgene for novel immunomodulatory therapies
- Philogen collaborates with Novartis for the research and development of immunomodulatory candidates. In 2017 & 2016- Philogen also collaborated with Boehringer Ingelheim (BI) and Pfizer to develop and commercialize DNA-encoded therapies & ADCs for multiple therapy areas respectively
Click Here Ref: Philogen | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
